Cara Therapeutics Inc

Ticker CARA

Exchange NASDAQ More
Industry Biotechnology More
Sector Healthcare More

51-200 Employees
Based in Stamford, Connecticut

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment to improve the lives of patients suffering from pruritus. The company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA and EMA approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The company is developing an…More

Visit website

REPORT RATINGS

4.8 / 5.0 (177)

Cara Therapeutics Inc reports have an aggregate usefulness score of 4.8 based on 177 reviews.

Cara Therapeutics Inc

Most Recent Annual Report

MOST RECENT 2022 Annual Report and Form 10K

View PDF View Form 10K (HTML)

Cara Therapeutics Inc does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Please fill out the form below and click "Place Order" to complete your order.